BDSX · XBRL financial data

Biodesix financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BDSX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	45,557	54,506	38,212	49,087	71,323	88,499
Research and development	10,818	12,789	13,102	9,988	9,559	12,001
Selling, general and administrative	34,857	50,517	61,462	67,387	80,451	87,545
Total operating expenses	68,491	95,446	88,799	90,429	105,821	116,372
Operating income (loss)	(22,934)	(40,940)	(50,587)	(41,342)	(34,498)	(27,873)
Interest expense	7,604	4,508	8,072	9,536	8,258	7,716
Other income (expense)	(8,416)	(2,219)	(14,860)	(10,804)	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(31,350)	(43,159)	(65,447)	(52,146)	(42,931)	(35,265)
Earnings per share, basic‡ USD per share	—	(31.60)	(31.00)	(12.80)	(6.60)	(4.67)
Earnings per share, diluted‡ USD per share	—	(31.60)	(31.00)	(12.80)	(6.60)	(4.67)
Weighted average shares, basic‡ thousands of shares	—	1,368	2,105	4,106	6,484	7,551
Weighted average shares, diluted‡ thousands of shares	—	1,368	2,105	4,106	6,484	7,551

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Fiscal years (BDSX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	62,126	32,712	43,088	26,284	26,245	18,987
Accounts receivable	15,304	3,656	5,065	7,679	8,603	9,036
Total current assets	86,140	43,613	53,334	39,683	39,484	32,518
Property and equipment, net	3,178	4,179	5,848	27,867	27,828	24,817
Right-of-use asset	—	1,500	2,973	1,745	1,767	2,997
Goodwill	15,031	15,031	15,031	15,031	15,031	15,031
Total assets	121,070	76,097	92,906	99,096	97,244	87,476
Accounts payable	8,964	1,662	1,685	2,929	2,194	3,080
Accrued liabilities	7,789	7,665	8,218	7,710	10,064	11,033
Total current liabilities	32,125	28,960	22,839	33,416	14,317	17,436
Lease liability, non-current	—	—	5,254	25,163	24,828	24,039
Total liabilities	79,904	56,370	72,300	94,516	76,368	89,941
Accumulated deficit	(258,814)	(301,973)	(367,420)	(419,566)	(462,497)	(497,762)
Total stockholders' equity	41,166	19,727	20,606	4,580	20,876	(2,465)
Total liabilities and equity	121,070	76,097	92,906	99,096	97,244	87,476
Common shares outstanding (cover page)‡ thousands of shares	1,329	1,565	3,899	4,847	7,299	9,858

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Fiscal years (BDSX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(31,350)	(43,159)	(65,447)	(52,146)	(42,931)	(35,265)
Stock-based compensation	3,709	4,944	5,961	5,373	6,638	4,139
Net cash from operating activities	(21,366)	(28,223)	(44,972)	(22,870)	(48,649)	(23,271)
Purchases of property and equipment	1,945	2,241	3,298	22,919	3,230	259
Net cash from investing activities	(2,927)	(2,547)	(3,534)	(23,062)	(3,440)	(403)
Proceeds from issuing common stock	—	16,343	59,538	28,126	55,625	7,320
Repayments of long-term debt	—	45,428	28,604	49	51	21
Net cash from financing activities	81,131	1,262	58,882	29,129	52,050	16,417
Net change in cash	56,838	(29,508)	10,376	(16,803)	(39)	(7,257)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Biodesix	28,409	24,041	(7,203)*	11.1M	4.3 quarters	Q3 FY26 10-QSep 30, 2026
American Shared Hospital Services	6,511	8,430	2,236*	6.7M	—	Q2 FY26 10-QJun 30, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Ludwig Enterprises	18	not reported	(153)	167.2M	1.3 quarters	Q1 FY26 10-QMar 31, 2026
BioNexus Gene Lab	1,233	76	(422)*	2.9M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Sera Prognostics	3,986	42	(7,298)*	not reported	5.9 quarters	Q3 FY26 10-QSep 30, 2026
Aclarion	14,188	34	not reported	2.9M	—	Q3 FY26 10-QSep 30, 2026
Freenome	437	not reported	(130)*	not reported	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 8:05 PM ET. The filing on SEC.gov is the record.